当前位置: X-MOL 学术Adv. Funct. Mater. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Single‐Shot Mesoporous Silica Rods Scaffold for Induction of Humoral Responses Against Small Antigens
Advanced Functional Materials ( IF 19.0 ) Pub Date : 2020-07-16 , DOI: 10.1002/adfm.202002448
Maxence O. Dellacherie 1, 2 , Aileen Li 1, 2 , Beverly Y. Lu 1, 2 , Catia S. Verbeke 1, 2 , Luo Gu 1, 2 , Alexander G. Stafford 2 , Edward J. Doherty 2 , David J. Mooney 1, 2
Affiliation  

Vaccines have shown significant promise in eliciting protective and therapeutic responses. However, most effective vaccines require several booster shots, and it is challenging to generate responses against synthetic molecules and peptides often used to increase target specificity and improve vaccine stability. As continuous antigen uptake and processing by antigen‐presenting cells and persistent toll‐like receptor priming can amplify humoral immunity, it is explored whether a single injection of a mesoporous silica micro‐rod (MSR) vaccine containing synthetic molecules and peptides can generate potent and durable humoral immunity. A single injection of the vaccine targeting a gonadotropin‐releasing hormone (GnRH) decapeptide elicits high anti‐GnRH titer for over 12 months and generated higher titers than bolus or alum formulations. Targeting a Her2/neu peptide within the Trastuzumab binding domain causes immunoreactivity to Her2 on tumor cells and, MSR vaccines against nicotine generated long‐term anti‐nicotine antibodies. A single MSR injection induced germinal center (GC) activity for more than 3 weeks, generated memory B cells, and 7 days of immunostimulation by the vaccine is required to generate effective antibody responses. The MSR vaccine represents a promising technology to bypass the need for multiple immunizations and enhance long‐term antibody production in the context of reproductive biology, cancer, and chronic addiction.

中文翻译:

单发中孔硅胶棒支架诱导对小抗原的体液反应。

疫苗在引发保护性和治疗性反应方面显示出巨大的希望。然而,最有效的疫苗需要多次加强注射,而针对通常用于增加靶标特异性和改善疫苗稳定性的合成分子和肽产生反应具有挑战性。由于抗原呈递细胞对抗原的持续摄取和加工以及持续的toll样受体引发可以增强体液免疫,因此我们探索了单次注射含有合成分子和肽的中孔二氧化硅微棒(MSR)疫苗是否可以产生有效的抗病毒药物。持久的体液免疫。靶向促性腺激素释放激素(GnRH)十肽的单次注射疫苗会产生超过12个月的高抗GnRH滴度,并且比推注或明矾制剂产生更高的滴度。在曲妥珠单抗结合域内靶向Her2 / neu肽可导致肿瘤细胞对Her2产生免疫反应,而针对尼古丁的MSR疫苗可产生长期抗烟碱抗体。要产生有效的抗体反应,需要单次MSR注射诱导生发中心(GC)活动超过3周,产生记忆B细胞,并需要7天的疫苗免疫刺激。MSR疫苗代表了一种有前途的技术,可以在生殖生物学,癌症和慢性成瘾的背景下绕开多次免疫的需要并提高长期抗体的产生。要产生有效的抗体反应,需要单次MSR注射诱导生发中心(GC)活动超过3周,产生记忆B细胞,并需要7天的疫苗免疫刺激。MSR疫苗代表了一种有前途的技术,可以在生殖生物学,癌症和慢性成瘾的背景下绕开多次免疫的需要,并提高长期抗体的产生。要产生有效的抗体反应,需要单次MSR注射诱导生发中心(GC)活动超过3周,产生记忆B细胞,并需要7天的疫苗免疫刺激。MSR疫苗代表了一种有前途的技术,可以在生殖生物学,癌症和慢性成瘾的背景下绕开多次免疫的需要并提高长期抗体的产生。
更新日期:2020-09-18
down
wechat
bug